A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
We hope to determine the maximum tolerated dose of 3 session (i.e., treatment) stereotactic radiosurgery to treat brain metastases greater than 4.2 cm3 in size. By increasing radiation dose, we will determine if there is a better outcome without greater toxicity (side effects) for patients.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Scott G. Soltys, MD
- Steven D. Chang, MD
- John R. Adler, MD
- Iris C. Gibbs, MD, FACR
- Griffith Harsh, MD
- Gordon Li, MD
- device : Linear accelerator
- procedure : Fractionated Stereotactic Radiosurgery
Phase: Phase 1/Phase 2
Ages Eligible For Study:
- All patients age 18 years and older with pathologically proven solid tumor malignancy and 1 to 4 brain metastases, one of which is 4.2 - 33.5 cm^3. - Systemic therapy: Prior cytoxic systemic therapy must be completed >= 5 days prior to radiosurgery. No concurrent cytoxic systemic therapy along with SRS. Cytoxic systemic therapy to start >= 5 days after the completion of SRS. - Prior surgery or SRS is allowed as long as the target metastatic lesion in this study has not previously been treated with SRS. - Patient must exhibit the ability to understand and the willingness to sign a written informed consent. - Life expectancy of at least 12 weeks.